Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: TAP's Prevacid

Executive Summary

TAP's Prevacid: AWP of Takeda-Abbott's proton pump inhibitor lansoprazole is $97.51 for 30 15 mg delayed-release capsules and $325 for 100 30 mg caps, Medi-Span reports. Per-month cost is lower than that for Astra Merck's Prilosec (omeprazole), which lists an AWP of $108.90 for 30 20 mg controlled-release caps. Prevacid was approved May 10 ("The Pink Sheet" May 15, p. 3)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026493

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel